Table 2.
Adherence and treatment failure among the three types of healthcare settings: n (%)
| Type of healthcare setting | ||||
|---|---|---|---|---|
| Public (n = 263) | Private (n = 59) | Public-private (n = 149) | P value | |
| ≥95% adherencea reported in previous one month | 256 (97.3) | 52 (88.1) | 139 (93.3) | 0.01 |
| Treatment interruption reported in previous 3 months | 2 (0.8) | 6 (10.2) | 8 (5.4) | 0.001 |
| Detectableb viral load | 35 (13.3) | 13 (22.0) | 14 (9.4) | 0.05 |
| CD4 ≥ 200 cells/mm3 | 207 (78.7) | 47 (79.7) | 119 (79.9) | n.s.d |
| Genotypingc performed | 29 (11.0) | 15 (25.4) | 19 (12.8) | 0.019 |
| Drug resistance-associated mutations present | 23 (8.7) | 12 (20.3) | 12 (8.1) | 0.029 |
a Adherence as measured by Visual Analogue Scale (VAS)
b Detectable viral load: > 100 copies/ml
c Genotyping was performed on those with viral load > 1000 copies/ml
d Not significant